3,441 Shares in Insulet Corporation $PODD Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC purchased a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,441 shares of the medical instruments supplier’s stock, valued at approximately $1,081,000.

A number of other institutional investors have also recently made changes to their positions in PODD. Vanguard Group Inc. increased its stake in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after buying an additional 178,976 shares during the period. American Century Companies Inc. grew its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Groupama Asset Managment increased its position in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after acquiring an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after acquiring an additional 27,408 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Insulet by 23.4% during the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after acquiring an additional 120,197 shares during the last quarter.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $336.84 on Thursday. The firm’s 50-day moving average price is $324.17 and its 200-day moving average price is $311.37. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a market cap of $23.70 billion, a PE ratio of 102.38, a PEG ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Stifel Nicolaus started coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. Leerink Partners increased their target price on Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. BTIG Research reiterated a “buy” rating and issued a $370.00 price target on shares of Insulet in a research note on Thursday, November 6th. Finally, Oppenheimer raised their price objective on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $374.10.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.